Notification of Disallowance - 13 June 2017

Overview

The Therapeutic Goods and Other Legislation Amendment (Narcotic Drugs) Regulation 2016 was enacted to address issues related to the regulation of narcotic drugs within Australia. The regulation was made under the authority of the Crimes Act 1914 and the Therapeutic Goods Act 1989, aiming to strengthen the control over the manufacture, distribution, and use of these substances. However, on 13 June 2017, the Senate passed a resolution disallowing certain items of the regulation, specifically items 1 and 4 of Schedule 1, indicating that the enacting body had concerns about the regulation's provisions. The disallowance highlights a gap in the regulation that was seen as potentially problematic, prompting the Senate to take action to ensure the legislative framework aligns with broader policy objectives for drug regulation and public safety.

Scope and Application

The disallowance notification pertains to the disallowance of specific items in the Therapeutic Goods and Other Legislation Amendment (Narcotic Drugs) Regulation 2016. This regulation, made under the Crimes Act 1914 and the Therapeutic Goods Act 1989, applies to the conduct and transactions concerning the classification, regulation, and control of therapeutic goods, specifically narcotic drugs, within Australia. The disallowance applies to the entire Commonwealth jurisdiction, encompassing all persons and entities involved in the manufacture, supply, and distribution of these goods. The disallowance does not specify any exclusions, exemptions, or thresholds; however, it does indicate that subordinate instruments may extend or restrict the application of these regulations. This disallowance by the Senate effectively nullifies items 1 and 4 of Schedule 1 of the Regulation, thereby altering the regulatory framework governing narcotic drugs in Australia.

Key Provisions

The key operative sections of the Therapeutic Goods and Other Legislation Amendment (Narcotic Drugs) Regulation 2016, as disallowed by the Senate on 13 June 2017, pertain to items 1 and 4 of Schedule 1. Item 1, which was disallowed, concerned the regulation of certain substances under the Narcotic Drugs Act 1967, specifically relating to the scheduling and classification of drugs. Item 4, also disallowed, addressed amendments to the Therapeutic Goods Act 1989, focusing on the oversight and administration of therapeutic goods, particularly those classified as narcotics. These sections imposed specific obligations and requirements on the parties and entities they govern. Under item 1, there were provisions aimed at ensuring that certain substances were properly scheduled and classified to control their availability and use effectively. This included stringent requirements for the manufacture, distribution, and possession of these substances. Item 4 established protocols for the oversight of therapeutic goods, ensuring that any goods classified as narcotics were subject to rigorous scrutiny and regulation to safeguard public health and safety. The regulation of these items also carried significant legal implications in the event of non-compliance. Breaches of these disallowed provisions could result in both civil and criminal consequences. For example, unauthorised possession, manufacture, or distribution of scheduled narcotics could lead to criminal charges, with penalties including substantial fines and imprisonment. Additionally, entities found in violation of the Therapeutic Goods Act 1989 could face administrative penalties, including fines and potential revocation of licenses or permits necessary for conducting business in the therapeutic goods sector. Maximum penalties for breaches related to these disallowed items varied depending on the severity and nature of the offence. For instance, individuals found guilty of serious drug-related offences could face imprisonment terms ranging from several years to life, alongside hefty fines. Under the Therapeutic Goods Act 1989, administrative penalties could reach up to $2,200,000 for corporations and $440,000 for individuals. These provisions underscore the seriousness with which the Australian legal system treats the unauthorised handling of narcotics and the importance of strict regulatory compliance.